Back to search results

eHealth Delivery Alternatives for Cancer Genetic Testing

This study, called eREACH3, is looking at how well telehealth (healthcare services delivered remotely) and digital tools work for people who need genetic testing for hereditary cancer. You might be interested if you have a personal or family history of cancer and meet national guidelines for genetic testing. The study aims to see how many people use these digital tools and remote genetic counseling, and how helpful they find them. You will receive genetic counseling at home, and digital tools are an optional part of the process. The study will measure how many people take part in the first counseling visit, the digital first visit, and genetic testing over six months.

Study design
This is an observational study with a planned enrollment of 360 participants. It is not specified if the study involves randomization or blinding.
What's involved
You will receive telehealth genetic counseling, which includes two genetic counseling visits. You may also be offered various optional digital tools to help with the counseling and testing process.
Compensation
Not stated in the trial record.
Follow-up
The study measures outcomes through 6 months after the initial visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07471958

Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3)

Recruiting
Not specifiedAges 18+Observational
Abramson Cancer Center at Penn Medicine
~360 participants
Updated 2026-03-13 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Uptake of Visit 1
Measured over Through 6 months
+2 more outcomes measured

Conditions

Cancer

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Angela Bradbury, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania

Who to contact

Angela Bradbury, MD
[email protected]
215-615-3341
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age or older
Speak and understand English
Meet current National Comprehensive Cancer Network (NCCN) or other national guidelines for germline genetic testing or are interested in genetic counseling based on personal or family history of cancer. Patients with prior genetic testing are eligible if they meet criteria for updated testing, or if post-test genetic counseling services are requested.

Exclusion

Communication difficulties such as:
Uncorrected or uncompensated hearing and/or vision impairment. Patients who can successfully use clinical assistance devices are not excluded.
Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded.
Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks

What this trial measures

  • Uptake of Visit 1Through 6 months

    Participant completion of Visit 1 (yes/no)

  • Uptake of Digital Visit 1Through 6 months

    Participant completion of digital intervention as an alternative for Visit 1 (yes/no)

  • Uptake of genetic testingThrough 6 months

    Participant completion of genetic testing and received results/Visit 2 (yes/no)